CL2011001692A1 - Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros. - Google Patents
Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.Info
- Publication number
- CL2011001692A1 CL2011001692A1 CL2011001692A CL2011001692A CL2011001692A1 CL 2011001692 A1 CL2011001692 A1 CL 2011001692A1 CL 2011001692 A CL2011001692 A CL 2011001692A CL 2011001692 A CL2011001692 A CL 2011001692A CL 2011001692 A1 CL2011001692 A1 CL 2011001692A1
- Authority
- CL
- Chile
- Prior art keywords
- colon
- type
- obesity
- glutamine
- diabetes
- Prior art date
Links
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title abstract 4
- 210000001072 colon Anatomy 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000003629 gastrointestinal hormone Substances 0.000 title abstract 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 title 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Composición para inducir liberación de una hormona intestinal desde las células L en el colon, que comprende ácido butírico, un Ac. biliar, Ac. Graso de cadena larga y glutamina, formulada para que no se libere en estómago ni en tracto gi superior; y uso en el tratamiento y prevención de enfermedades tales como diabetes y obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14395109P | 2009-01-12 | 2009-01-12 | |
| US29377310P | 2010-01-11 | 2010-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001692A1 true CL2011001692A1 (es) | 2012-04-13 |
Family
ID=42317190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001692A CL2011001692A1 (es) | 2009-01-12 | 2011-07-11 | Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8470885B2 (es) |
| EP (1) | EP2376077B1 (es) |
| JP (1) | JP5702306B2 (es) |
| KR (4) | KR20170138573A (es) |
| CN (1) | CN102355896A (es) |
| AU (1) | AU2010203413B2 (es) |
| BR (1) | BRPI1006145B8 (es) |
| CA (1) | CA2748827C (es) |
| CL (1) | CL2011001692A1 (es) |
| CY (1) | CY1119010T1 (es) |
| DK (1) | DK2376077T3 (es) |
| EA (1) | EA022631B1 (es) |
| ES (1) | ES2628233T3 (es) |
| HR (1) | HRP20170886T1 (es) |
| HU (1) | HUE034551T2 (es) |
| LT (1) | LT2376077T (es) |
| MX (1) | MX2011007393A (es) |
| PL (1) | PL2376077T3 (es) |
| PT (1) | PT2376077T (es) |
| RS (1) | RS56054B1 (es) |
| SI (1) | SI2376077T1 (es) |
| SM (1) | SMT201700278T1 (es) |
| WO (1) | WO2010081079A2 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012509892A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ，インク． | サティオゲン類を含有する組成物及び使用の方法 |
| US20150224081A1 (en) * | 2009-01-12 | 2015-08-13 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US20220071895A1 (en) * | 2009-01-12 | 2022-03-10 | Biokier, Inc. | Composition and method for treatment of diabetes |
| WO2012161670A2 (en) | 2010-04-07 | 2012-11-29 | Incube Labs, Llc | Method for treating diabetes and other glucose regulation disorders using stem cells |
| CN109593814A (zh) | 2010-05-12 | 2019-04-09 | 哥伦比亚大学纽约管理委员会 | 筛选分析、鉴别药剂的方法及药物组合物 |
| CN103702668A (zh) * | 2011-05-02 | 2014-04-02 | 拜奥基尔公司 | 治疗糖尿病的组合物和方法 |
| KR20130055220A (ko) | 2011-11-18 | 2013-05-28 | 삼성전자주식회사 | 동박적층판 및 이를 사용한 금속코어기판의 제조방법 |
| EP3437649A1 (en) * | 2011-11-21 | 2019-02-06 | Emmaus Medical Inc. | Methods and compositions for the treatment of diabetes and related symptoms |
| US20150073057A1 (en) * | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
| WO2016172479A1 (en) * | 2015-04-22 | 2016-10-27 | Cedars-Sinai Medical Center | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes |
| US11291693B2 (en) | 2015-06-25 | 2022-04-05 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
| US9668991B1 (en) | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
| CN107684550B (zh) * | 2016-08-03 | 2020-04-10 | 徐天宏 | 糖尿病治疗产品及其制备与应用 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| WO2019165309A1 (en) | 2018-02-23 | 2019-08-29 | Ambra Bioscience Llc | Compositions and methods for hunger control and weight management |
| US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| MX2022001865A (es) | 2019-08-12 | 2022-03-11 | Massachusetts Inst Technology | Articulos y metodos para la administracion de agentes terapeuticos. |
| US20230190686A1 (en) * | 2021-12-17 | 2023-06-22 | Biokier, Inc. | Composition and method for treatment of diabetes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA885473B (en) | 1987-08-07 | 1989-03-29 | Century Lab Inc | Free fatty acids for treatment of diabetes mellitus |
| IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6652882B1 (en) | 1997-10-06 | 2003-11-25 | Intellipharmaceutics Corp | Controlled release formulation containing bupropion |
| GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| DE60005819T2 (de) | 1999-06-14 | 2004-05-06 | Cosmo S.P.A. | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe |
| US7087579B2 (en) | 2001-02-26 | 2006-08-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| US20030203004A1 (en) | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| DE60300502T2 (de) | 2003-10-28 | 2006-02-23 | Adorkem Technology S.P.A., Costa Volpino | Verfahren zur Herstellung von Citalopram |
| ITMI20040187A1 (it) | 2004-02-06 | 2004-05-06 | Cosmo Spa | Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali |
| ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| JP2006056881A (ja) | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| CA2609394A1 (en) | 2005-05-23 | 2006-11-30 | Masaki Takagi | Pyrazole compound and therapeutic agent for diabetes comprising the same |
| DE102005046237A1 (de) | 2005-09-28 | 2007-04-05 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen |
| ITMI20052000A1 (it) | 2005-10-21 | 2007-04-22 | Promefarm S R L | Compressa gastroresitente a base di butirrato di sodio |
| EA200801551A1 (ru) | 2006-01-20 | 2009-02-27 | Смитклайн Бичем Корпорейшн | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы |
| US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| WO2008071790A2 (en) * | 2006-12-15 | 2008-06-19 | Tima Foundation | Novel compositions and uses thereof |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| JP2012509892A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ，インク． | サティオゲン類を含有する組成物及び使用の方法 |
| ES2768091T3 (es) | 2009-02-10 | 2020-06-19 | Amarin Pharmaceuticals Ie Ltd | Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
-
2010
- 2010-01-11 US US13/143,766 patent/US8470885B2/en active Active
- 2010-01-11 PL PL10729620T patent/PL2376077T3/pl unknown
- 2010-01-11 HR HRP20170886TT patent/HRP20170886T1/hr unknown
- 2010-01-11 KR KR1020177034790A patent/KR20170138573A/ko not_active Ceased
- 2010-01-11 CA CA2748827A patent/CA2748827C/en active Active
- 2010-01-11 EA EA201190068A patent/EA022631B1/ru unknown
- 2010-01-11 AU AU2010203413A patent/AU2010203413B2/en not_active Ceased
- 2010-01-11 ES ES10729620.4T patent/ES2628233T3/es active Active
- 2010-01-11 WO PCT/US2010/020629 patent/WO2010081079A2/en not_active Ceased
- 2010-01-11 MX MX2011007393A patent/MX2011007393A/es active IP Right Grant
- 2010-01-11 RS RS20170584A patent/RS56054B1/sr unknown
- 2010-01-11 SI SI201031473T patent/SI2376077T1/sl unknown
- 2010-01-11 JP JP2011545487A patent/JP5702306B2/ja active Active
- 2010-01-11 KR KR1020117015982A patent/KR20110120866A/ko not_active Ceased
- 2010-01-11 PT PT107296204T patent/PT2376077T/pt unknown
- 2010-01-11 BR BRPI1006145A patent/BRPI1006145B8/pt not_active IP Right Cessation
- 2010-01-11 CN CN201080004432XA patent/CN102355896A/zh active Pending
- 2010-01-11 DK DK10729620.4T patent/DK2376077T3/en active
- 2010-01-11 KR KR1020177007518A patent/KR20170034928A/ko not_active Ceased
- 2010-01-11 LT LTEP10729620.4T patent/LT2376077T/lt unknown
- 2010-01-11 KR KR1020197015093A patent/KR20190062609A/ko not_active Ceased
- 2010-01-11 EP EP10729620.4A patent/EP2376077B1/en active Active
- 2010-01-11 SM SM20170278T patent/SMT201700278T1/it unknown
- 2010-01-11 HU HUE10729620A patent/HUE034551T2/en unknown
-
2011
- 2011-07-11 CL CL2011001692A patent/CL2011001692A1/es unknown
-
2012
- 2012-10-08 US US13/646,778 patent/US8680085B2/en not_active Expired - Fee Related
-
2017
- 2017-06-12 CY CY20171100614T patent/CY1119010T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200600297A (es) | Nuevos anticuerpos anti-madcam | |
| EA201190068A1 (ru) | Композиция и способ лечения диабета | |
| CO6511276A2 (es) | Composición probiótica para uso en el tratamiento de la inflamación del intestino | |
| MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
| HN2011003218A (es) | Peptidos especificos para receptores de melanocortina | |
| CY1119596T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| CL2011000099A1 (es) | Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria. | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| CR20110509A (es) | Composicion farmaceutica | |
| CL2009000120A1 (es) | Compuestos derivados de carboxamidas n-aza-biciclicas; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso como antagonistas o agonistas del receptor tipo trpv1 para tratar el dolor, la inflamacion, trastornos metabolicos, urologicos, ginecologicos, gastrointestinales, respiratorios. | |
| CL2011002745A1 (es) | Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras. | |
| UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
| CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
| CO6430487A2 (es) | Anticuerpos anti-her | |
| CO6400193A2 (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
| CL2012000738A1 (es) | Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras. | |
| ECSP12011593A (es) | Análogos de glucagón acilados | |
| DOP2012000246A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| MX2012003459A (es) | Composicion y metodo para el tratamiento de la diabetes. | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| UY32778A (es) | Terapia de combinación para el tratamiento de la diabetes | |
| EA201390194A1 (ru) | Улучшенный рекомбинантный фолликул-стимулирующий гормон человека | |
| EA201490637A1 (ru) | Растительные стероиды и их применения |